In the latest trading session,, 0.96 million 10x Genomics Inc (NASDAQ:TXG) shares changed hands as the company’s beta touched 1.87. With the company’s most recent per share price at $7.62 changing hands around $0.48 or 6.65% at last look, the market valuation stands at $931.35M. TXG’s current price is a discount, trading about -395.28% off its 52-week high of $37.74. The share price had its 52-week low at $6.78, which suggests the last value was 11.02% up since then. When we look at 10x Genomics Inc’s average trading volume, we note the 10-day average is 3.21 million shares, with the 3-month average coming to 2.98 million.
Analysts gave the 10x Genomics Inc (TXG) stock a consensus recommendation rating of Hold, calculated at a mean rating of 2.40. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 5 recommended TXG as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. 10x Genomics Inc’s EPS for the current quarter is expected to be -0.29.
10x Genomics Inc (NASDAQ:TXG) trade information
Instantly TXG is in green as seen in intraday trades today. With action -13.95%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -46.97%, with the 5-day performance at -13.95% in the red. However, in the 30-day time frame, 10x Genomics Inc (NASDAQ:TXG) is -29.56% down. Looking at the short shares, we see there were 12.08 million shares sold at short interest cover period of 3.63 days.
The consensus price target for the stock as assigned by Wall Street analysts is 25, meaning bulls need an upside of 69.52% from its recent market value. According to analyst projections, TXG’s forecast low is 24 with 46 as the target high. To hit the forecast high, the stock’s price needs a -503.67% plunge from its current level, while the stock would need to soar -214.96% for it to hit the projected low.
10x Genomics Inc (TXG) estimates and forecasts
Year-over-year growth is forecast to reach -0.11% down from the last financial year.
Consensus estimates given by 14 financial analysts project the company’s revenue in the current quarter to hit an average of 131.72M. 14 analysts are of the opinion that 10x Genomics Inc’s revenue for the current quarter will be 145.36M. The company’s revenue for the corresponding quarters a year ago was 141.01M and 153.1M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -6.59%. The estimates for the next quarter sales put growth at -5.06%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -36.10%. The 2025 estimates are for 10x Genomics Inc earnings to decrease by -0.12%, but the outlook for the next 5-year period is at 15.97% per year.
10x Genomics Inc (NASDAQ:TXG)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.36% of 10x Genomics Inc shares while 96.92% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 99.27%. There are 96.92% institutions holding the 10x Genomics Inc stock share, with FMR LLC the top institutional holder. As of 2024-06-30, the company held 10.836% of the shares, roughly 13.01 million TXG shares worth $253.05 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 8.5341% or 10.19 million shares worth $198.18 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were ARK ETF Trust-ARK Innovation ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 8.67 shares estimated at $65.35 million under it, the former controlled 8.01% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 2.94% of the shares, roughly 3.18 shares worth around $24.0 million.
